All News
MRI as a novel biomarker in lupus
The clinical abstract sessions on diagnostic tools in lupus showcased interesting studies, including the use of MRI as potential non-invasive biomarkers.
Read Article
Digital Platforms and AI
2026 EULAR Press Release
EULAR works with the network of national organisations of People with Arthritis/Rheumatism in Europe (PARE) to ensure the voices of people with RMD are heard and have influence – creating powerful alliances that make a real difference. Artificial intelligence is another potential ally in that fight. At the EULAR 2026 Congress in London, work was presented from three PARE initiatives that showcase how digital tools can be used in treatment education and decision-making, and potentially avoid the use of general web searches to answer important questions.
Read Article
#EULAR2026 OP0336 Exploratory study of REGENCY RCT showed Obinutuzumab induced tissue depletion & histologic remission vs PBO. Interestingly, 53% OBI CRR non-responders had histologic remission. Better #lupus nephritis markers needed beyond proteinuria @RheumNow #EULARBest https://t.co/d8jPo9scvw
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2026 OP0335 Open label extension study of Phase II Ianalumab RCT in #SLE: some patients treated with IAN for up to 1 year, had persistent benefits (median 44 wks post-IAN) following Bcell recovery. Important info to judiciously treat while balancing infection risk @RheumNow https://t.co/DEkGMYwy3H
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Dr. Laura Andreoli shares this slide showing the impact of rheumatic disease in reproductive health as described by Dr. MOstensen.
These interplay of factors affect patients and should be taken into consideration when managing fertility & pregnancy.
@RheumNow #EULAR2026 https://t.co/fB9kuD4kXo
sheila RHEUMarampa ( View Tweet)
#OP0337 In 48-week WILLOW🌳 LTE, oral TLR7/8 inhibitor enpatoran showed sustained improvements in cutaneous lupus activity with high CLASI-50/70 response rates and consistent safety profile across doses. Encouraging long-term data for CLE/SLE skin disease. #EULAR2026 @RheumNow https://t.co/6y0HjaTMqh
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2026 OP0337 In double blind LTE WILLOW study, cutaneous efficacy (change in CLASI, CLASI 70/50) was maintained in Enpatoran, TLR 7/8-i by WK48. Those switched from PBO to ENP at WK24 also showed equal efficacy to ENP-ENP group. Promising treatment for #CLE #lupus @RheumNow https://t.co/0Plpy6c8At
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2026 OP0220 How can we improve physical function of #SLE patients? Cross-sectional study of 2 US cohorts: poor physical function was associated with Fatigue, depression, learned helplessness and perceived stress. We should focus on improving fatigue & wellbeing @RheumNow https://t.co/vAFqYyuzgN
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
From Skepticism to Reconsideration: 4‑Year CAR‑T Outcomes in Lupus
Chimeric antigen receptor (CAR) T‑cell therapy, long established in hematologic malignancies, is now emerging as a transformative approach in systemic lupus erythematosus (SLE), a disease historically managed https://t.co/Dmmw90XnuF
Dr. John Cush RheumNow ( View Tweet)
Progress of biologics/targeted therapy in SLE
We are in a transformative era for SLE, for clinicians and patients. Four targeted therapies are now licensed: belimumab (nephritis and non‑renal), voclosporin and obinutuzumab (nephritis), and anifrolumab (non‑renal). Many agents https://t.co/BuFCmj1hQd
Dr. John Cush RheumNow ( View Tweet)
DR JOHN STONE gives Overview
Of
#IgG4
New non B cell depleter
#obexelimab N=194 in RCT
To add to B cell depletion w
#Inebilizumab
Off label but used also
#Rituximab
#steroids
#Immunesuppressives
Other investigational drugs
Ex #JAKi
#EULAR2026 @RheumNow
#OP018 #RULARbest https://t.co/Y4saGYcdww
Links:
Janet Pope Janetbirdope ( View Tweet)
Good news! #Survival in #SLE is improving
#SLR of #lupus publications over time in 233 publications
Bad news - still a mortality gap!
#EULAR2026
@RheumNow @eular_org
ABST#POS0684 https://t.co/PVmQI2duYS
Janet Pope Janetbirdope ( View Tweet)
Sustained remission in #SLE at 5 yrs w CAR-T
8 severe SLE patients treated with
autologous CD19-CAR T cells
(Zorpocel; Miltenyi Biomedicine)
#antiDNA and #SLEDAI #antiSm ➡️prolonged suppression
Big ? - how long will it work for
Impressive!
@RheumNow #EULAR2026
#EULARbest #729 https://t.co/8iOSImX3w6
Janet Pope Janetbirdope ( View Tweet)
Defining the TRM- SLE patient response.
Patient eligibility would be the key
#EULAR2026 @RheumNow https://t.co/5CzQYgc12K
Links:
Bella Mehta bella_mehta ( View Tweet)
Treatment for #lupus #brain #fog?!
#small #RCT of Memantine a N-methyl-D-aspartate receptor (NDAR) antagonist used in #Alzheimers
SLE-more permeability in #brain #SLE -antiDNA cross reacting w NDAR
#memantine N=19 v #PBO N=25 showed more improvemt
#EULAR2026 @RheumNow POS701 https://t.co/qvHOy9oDS7
Janet Pope Janetbirdope ( View Tweet)
#EULAR2026 POS0079 Phase I study of “Off-the-Shelf” CD19 CAR-T FT819 in N=13 #SLE pts with/-out LN reported favourable efficacy and safety particularly with Bendamustine conditioning. Advantages: scalable and requires minimal or no conditioning. Will move on to Phase II @RheumNow https://t.co/2rt646Qf0T
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
ClearMEMory: Ph2 RCT evaluating memantine for tx of cognitive impairment in SLE using RBANS as outcome measure
MEM grp had sig. higher change in RBANS TIScore upto wk 12 vs. PBO, esp. immediate memory index score
Potential adjunct tx for NPSLE?
AbsPOS0701 @RheumNow #EULAR2026 https://t.co/UffdVPRu6s
sheila RHEUMarampa ( View Tweet)
@RheumNow WIN Nutrition session at #EULAR2026 (3)
6.🍟 High UPF intake → increased RA risk (HR 1.06/SD), partly mediated by CRP. Not all NOVA-4 foods are equal
7.💊 Vit D supplementation significantly reduces SLE disease activity — MA of 10 RCTs, SMD −0.54 (p<0.00001).
@RheumNow
Nelly ZIADE 🍀 Nellziade ( View Tweet)
WIN Nutrition session at #EULAR2026 (2)
🐟 n-3 PUFAs reduce RA risk by 9–10% per SD increase — especially in genetically high-risk individuals.
🫒 Mediterranean diet reduces RA risk by 25% (HR 0.75) & SLE risk by 39% (HR 0.61) in UK Biobank studies.
@RheumNow
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Prof. Wittmann discusses the current tx for CLE using a stepwise approach.
Smoking is a challenge in D2T skin #lupus due to data showing that smoking reduces efficacy of antimalarials & worsens dse act & damage.
Advocate for smoking cessation!
@Rheumnow #EULAR2026 https://t.co/pEWLJAkBAJ
Links:
sheila RHEUMarampa ( View Tweet)
